The Division of Gynecologic Oncology within the Department of Obstetrics and Gynecology, and the Cancer Center of the University of Rochester School of Medicine, proposes to use its membership in the Gynecologic Oncology Group (GOG) to maximally promote and utilize the multi-modality approach to the cancer care of women with reproductive organ malignancies, by participation in controlled clinical trials and studies of new anti-cancer agents. Major emphasis will be placed on the following: a) Continued accession of eligible patients with gynecologic cancer to Phase III, Phase II, and pilot studies in the chemotherapeutic, surgical and radiation modalities. b) Continued initiation and development of Phase II and Phase III studies for the GOG, some of which wil be based on on-going programs within the Experimental Therapeutic Division of the University of Rochester Cancer Center. c) Expansion of patient accessibility to these studies in Upstate New York, through further increases in outreach education and participation at various regional, hospital-based gynecologic Tumor Boards. d) Representation of fields of expertise on GOG disease site and modality committees. e) Promotion of collaborative studies between the GOG and Radiation Therapy Oncology Group (RTOG), initially through joint protocols in sarcomas, bulky cervic tumors and minimal residual ovarian cancer, and subsequently in other areas. f) Data collection, monitoring, quality control, reporting and publication of information. g) Utilization of the GOG as a unique national resource for the training of gynecologic oncologists, radiation oncologists, medical oncologists, pathologists, oncology nurses and data managers. h) Continued suppport of cancer education for medical students, residents in obstetrics and gynecology, nurses and nursing students, oncopharmacologists and pharmacists, enterostomy therapists, social workers, and health related personnel in the field of cancer care and treatment.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Rochester
Schools of Medicine
United States
Zip Code
Sutton, Gregory; Axelrod, Janice H; Bundy, Brian N et al. (2006) Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 100:349-54
Tate Thigpen, J; Blessing, John A; DeGeest, Koen et al. (2004) Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 93:336-9
Thigpen, J Tate; Blessing, John A; Olt, George et al. (2003) Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 90:581-6
Zaino, R; Whitney, C; Brady, M F et al. (2001) Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol 83:355-62
Hernandez, E; Donohue, K A; Anderson, L L et al. (2000) The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78:137-42
Zaino, R J; Kurman, R J; Brunetto, V L et al. (1998) Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study. Am J Surg Pathol 22:1379-85
Williams, L; Brunetto, V L; Yordan, E et al. (1997) Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 66:171-8
Ollila, D W; Essner, R; Wanek, L A et al. (1996) Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 131:975-9;979-80
Currie, J L; Blessing, J A; McGehee, R et al. (1996) Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 61:94-6
Look, K Y; Brunetto, V L; Clarke-Pearson, D L et al. (1996) An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 63:304-11

Showing the most recent 10 out of 40 publications